Drug research involves scientific discovery, technological inventions and product development. This multiple dimensional effort embodies both high risk and high reward and is considered one of the most complicated human activities. Prior to the initiation of a program, an in-depth analysis of "what to do" and "how to do it" must be conducted. On the macro level, market prospects, capital required, risk assessment, necessary human resources, etc. need to be evaluated critically. For execution, drug candidates need to be optimized in multiple properties such as potency, selectivity, pharmacokinetics, safety, formulation, etc., all with the constraint of finite amount of time and resources, to maximize the probability of success in clinical development. Drug discovery is enormously complicated, both in terms of technological innovation and organizing capital and other resources. A deep understanding of the complexity of drug research and our competitive edge is critical for success. Our unique government-enterprise-academia system represents a distinct advantage. As a new player, we have not heavily invested in any particular discovery paradigm, which allows us to select the optimal approach with little organizational burden. Virtue R&D model using CROs has gained momentum lately and China is a global leader in CRO market. Essentially all technological support for drug discovery can be found in China, which greatly enables domestic R&D efforts. The information technology revolution ensures the globalization of drug discovery knowledge, which has bridged much of the gap between China and the developed countries. The blockbuster model and the target-centric drug discovery paradigm have overlooked the research in several important fields such as injectable drugs, orphan drugs, and following high quality therapeutic leads, etc. Prejudice against covalent ligands, prodrugs, nondrug-like ligands can also be taken advantage of to find novel medicines. This article will discuss the current challenges and future opportunities for drug innovation in China.
Academies and Institutes ; Biomedical Research ; China ; Drug Costs ; Drug Design ; Drug Discovery ; economics ; Industry ; economics ; Investments ; economics ; Orphan Drug Production ; Public-Private Sector Partnerships

The development of new drugs and medical devices has been attributed to constant innovation, and the medical device industry in particular is growing faster than the drug industry. The medical device market in Korea is growing, with an average annual growth rate of 12.6% from 2006 to 2008. The production amount of medical devices categorized as Class 3 or Class 4 increased more rapidly than Class 1 or Class 2 with an increase in portion size. Clinical trials are a crucial process through which the safety and efficacy of medical devices is evaluated prior to allowing them to be used by the public. Recently, the approval rate of clinical trials for medical devices by the Korea Food & Drug Administration has increased, indicating that clinical trials that could be scientifically feasible and ethically justified were planned. To satisfy the increasing need for high quality clinical trials, a total of 6 medical device clinical trial center consortia have been designated by the Ministry of Health & Welfare as of July 2010. Medical devices take significantly less time to get to the market compared to drugs and there is much need for innovation. Therefore, the clinical trial market for new medical devices is expected to grow faster than previously forecast.
Drug Industry ; Korea

No abstract available.
Drug Industry* ; Prescriptions*

No abstract available.
Drug Industry* ; Prescriptions*

Objects: labour force capital and labour market in some pharmaceutical manufacturing enterprises during years of 1991-1994. Methods: efficacy of working, labour cost, studying and building a period of business, manufacture. High evaluation on needs of human resource, who were trained to become enough standard for moral and talent in arranged sites and close technical process.
Pharmaceutical Preparations ; Drug Industry

After The 6th Party Congress, Vietnam pharmaceutical industry prospered, especially in 1990s. Pharmaceutical industry was rising; drug market in Vietnam became eventful and plentiful, responded more and more effectively for the healthcare needs of people. The author mentioned situations of pharmaceutical production and trade in Vietnam during 1996-2002 period: kinds of pharmaceutical companies, situation of drug use, situation of production and trade of Vietnamese pharmaceutical companies and ensuring drug quality
Drug Industry ; Pharmaceutical Preparations

OBJECTIVETo optimize the objective technical parameter for direct processing technology of fresh-cut for Paeonia Radix Alba.

METHODPeoniflorin and TGP were employed as the indexes of quality evaluation. Combining with the appearance of the slices, we investigated the influence of slice degree and thickness, drying temperature, drying time, drying method and other factors on the quality control of Paeonia Radix Alba slices. Furthermore, the key fresh-cut technology operating procedures parameter for Paeonia Radix Alba in Bozhou was established based on the semi-works production.

RESULTIt established tentatively the method for fresh-out and fresh-out after boiled of Paeonia Radix Alba as that selected fresh or beiled Paeonia Radix Alba, then divided them from different grades and put them into a roller to crash off the skin, cleaned and then dried them 9 h at 60 degrees C (water content 28% - 32%), and then moistened 2-3 h after spraying moderate water. Cut them into 1.5-2 mm decoction pieces and dried them at 60 degrees C, cooled, and sealed them in a package.

CONCLUSIONThe industrialization of processing decoction pieces with freshly cut Paeonia Radix Alba is stable shortens processing time, avoids effectively sulfur fumigation and infiltrating and soften, and keep high quality of production.

To observe the layout and evolution of the traditional Chinese medicine (TCM) medical industry, classify the industry by region and conduct a preliminary study on its professional advantages, competitiveness and possible cause by using the theory of location quotient in regional economics, in order to provide suggestions for the layout of the TCM medical industry.
Drug Industry ; Medicine, Chinese Traditional

Analyzing traditional Chinese medicine industry from the view of industry chain, we find that there being many problems in industrial chain of traditional Chinese medicine, such as imbalanced industrial links, weak capability of innovation, low degree of information and resource depletion. This paper gives a in-depth analysis on causes of these problems in view of construction and integration of industrial chain to make basis of proposing countermeasures of developing traditional Chinese medicine industry.
Drug Industry ; Medicine, Chinese Traditional

This paper summarizes the current situation and restricting factors of the Yunnan traditional Chinese medicine industry. With further analysis comparing, the research puts forward some suggestions and strategic countermeasures to promote the development of the Yunnan traditional Chinese medicine industry.
Drug Industry ; Medicine, Chinese Traditional